TABLE 2.
Patient demographics
| No. of Patients (%) | |||
|---|---|---|---|
| Characteristic | All | Schedule A | Schedule B |
| N | 43 | 23 | 20 |
| Age, years | |||
| Median | 56 | 55 | 56 |
| Range | 37–76 | 37–70 | 43–76 |
| Gender | |||
| Male | 21 (48.8) | 9 (39.1) | 12 (60) |
| Female | 22 (51.1) | 14 (60.8) | 8 (40) |
| ECOG PS | |||
| 0 | 17 (39.5) | 10 (43.4) | 7 (35) |
| 1 | 24 (55.8) | 11 (47.8) | 13 (65) |
| 2 | 2 (4.6) | 2 (8.7) | 0 (0) |
| Primary cancer | |||
| Breast | 11 (25.6) | 9 (39.1) | 2 (10) |
| Pancreas | 7 (16.3) | 3 (13) | 4 (20) |
| Colorectal | 4 (9.3) | 0 (0) | 4 (20) |
| Non‐melanoma skin | 3 (6.9) | 3 (13) | 0 (0) |
| Non‐small cell lung | 3 (6.9) | 0 (0) | 3 (15) |
| Ovarian | 3 (6.9) | 3 (13) | 0 (0) |
| Other a | 12 (27.9) | 5 (21.7) | 7 (35) |
| Prior lines of cytotoxic therapy | |||
| 0 | 14 (32.5) | 9 (39.1) | 5 (25) |
| 1 | 15 (34.8) | 9 (39.1) | 6 (30) |
| ≥2 | 14 (32.5) | 5 (21.7) | 9 (45) |
| Prior PARP inhibitor | 5 (11.6) | 2 (8.7) | 3 (15) |
| Germline BRCA mutation status | |||
| gBRCA1mut | 7 (16.3) | 5 (21.7) | 2 (10) |
| gBRCA2mut | 10 (23.2) | 7 (30.4) | 3 (15) |
a
Includes prostate (2), urothelial (2), adenoid cystic carcinoma (2), head and neck squamous cell carcinoma (1), melanoma (1), uterine leiomyosarcoma (1), and one patient each with duodenal, esophageal, and gallbladder carcinoma.